Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,727 total articles
Meta's Muse rollout alters both the revenue runway and competitive dynamics. We upgrade the rating to a tactical buy: enter at $650.00, target $780.00, stop $560.00. The trade is driven by accelerating ad relevance, new commerce touchpoints, and a lower capital drag from Reality Labs as AI adoption scales. Risks include execution, regulation, and m…
Pfizer offers a mix of reliable cash generation, a 6.1% yield and an advancing R&D pipeline tied to autoimmune and vaccine-adjuvant innovation. At $28.44, the stock sits between its 52-week low and high and shows constructive technicals. This trade ideas targets a mid-term upside while protecting capital with a clear stop.
AC Immune (ACIU) is a clinical-stage neurodegeneration company trading at a $275m market cap. With recent price action near $2.70, modest technical support, and concentrated short interest, the risk/reward looks favorable for a mid-term swing ahead of ongoing ACI-7104 progress and potential pipeline expansion updates. This trade plan lays out an en…
Brookfield Corporation offers a pragmatic path to high shareholder returns: diverse fee-bearing asset management plus a large operating platform that benefits from asset recycling and selective acquisitions. At $36.56, Brookfield trades below key moving averages with an oversold RSI, a recent bolt-on acquisition that supports growth, and a market c…
Honeywell is trading cheap on headline multiples while its higher-margin software and building-automation exposures sit at the front end of multi-year secular growth. The recent post-spin reset and durable cash generation create a favorable risk-reward for a long, with a clear entry, stop and target over a 180 trading day horizon.
CRISPR Therapeutics is a clinical-stage gene-editing company whose shares have recently been buoyed by headlines around an AI developer's discovery that appears to accelerate protein and guide-RNA design. The combination of accelerating commercial revenue from Casgevy, improving margins, and a still-substantial valuation gap makes CRSP a tradable l…
McDonald's pulled back sharply after investor-day positioning, leaving the stock trading near its recent low with an oversold RSI and a 3.1% yield. Fundamentals remain intact: $7.4B in free cash flow, $12.42 EPS and a PE near 19.4. This trade idea lays out a swing buy plan with strict risk controls and a multi-horizon playbook.
Celestica (CLS) looks set to translate 2026 momentum into a 2027 growth phase driven by hyperscale AI demand and an expanding HealthTech portfolio. Fundamentals show improving margins, strong analyst revisions, and healthy cash generation — but the stock trades at a premium and execution risks remain. I lay out a long trade with entry, stop and tar…
DuPont (DD) combines a lean balance sheet, $1.05B of free cash flow and exposure to advanced materials end markets that are expanding on secular trends. At $131, the stock offers upside to prior highs if margins normalize and higher-value mix gains traction. We lay out an actionable long-term trade with entry, stop and target and the key catalysts …
AST SpaceMobile sits at the intersection of cellular and space infrastructure with patents that enable standard phones to connect directly to satellites. The stock trades on growth expectations, not today’s revenue; with $3.7B of reported liquidity and a pushed commercial launch to 2027, the setup is a clear binary trade. I am long with an entry at…
Western Digital (WDC) is trading well below levels justified by its cash generation, AI-driven demand growth and supply tightness for high-capacity storage. We lay out a long trade with concrete entry, stop and target, plus the catalysts and risks that could move the stock over the next 180 trading days.
Bitdeer is transitioning from a pure-play Bitcoin miner into a hybrid miner + AI colocation operator. Recent announcements of long-dated GPU leases (including a 16-year Tydal deal and multi-year Malaysian and A202 commitments) create a recurring revenue backbone. At a market cap of roughly $3.3B and AI Cloud ARR around $86M, the stock looks like a …
Kanzhun (BOSS Zhipin) is showing accelerating monetization after years of investment in product and AI. Q2 revenue growth of 14.1% with operating income up 32.6%, a growing shareholder-return program (> $530m combined) and a clear dividend/buyback commitment justify a long trade from current levels. Entry $14.32, target $18.00, stop $12.50; long te…
ANI Pharmaceuticals (ANIP) combines a cash-generative generics and established brands engine with an optionality-rich rare disease franchise centered on Cortrophin Gel. The stock trades at roughly $1.7B market cap, an EV/sales of ~2.0 and P/E in the mid-teens while management pushes toward $1B+ revenue. If a Q4 readout or commercial update for Cort…
Alphabet's valuation, cash flow profile and technical setup argue for a tactical long. The company trades at roughly $4.15T market cap, a P/E near 16.8 and generates $53.3B of free cash flow. With recent weakness and bullish technical signals starting to form, a mid-term long trade captures upside to a retest of the 52-week high while keeping risk …
A noisy bipolar mania trial readout appears to have compressed Rapport’s share price more than the underlying value of its anti-seizure candidate. We upgrade to Buy. The trade targets a recovery driven by clearer data interpretation, upcoming readouts, and re-anchoring of valuation as investors separate short-term signal noise from long-term seizur…
Acadia Pharmaceuticals ($ACAD) looks vulnerable after a recent run-up driven by a separate EU approval and institutional buying. The company trades at a ~ $4.05B market cap with a PE near 11.5 and meaningful cash on the balance sheet, but thin visibility on remlifanserin progress, oversold-but-volatile technicals, and elevated short interest create…
Grupo Aeroportuario del Sureste (ASR) is trading near its 52-week low despite durable cash flows from high-traffic airport concessions, a 2.16% dividend yield, and a sub-13x P/E. Technicals are oversold, short interest has climbed, and a reversion to historical multiples or recovery in tourism should push the stock considerably higher over a 180-tr…
Tesla's pullback back toward the $370s is a buying opportunity for a mid-term swing trade. Fundamentals show cash generation and scale advantages; technicals point to bullish momentum. This trade plans a disciplined entry at $375.00, a stop at $345.00 and a target at $430.00 over ~45 trading days.
Templeton's Q2 2026 commentary signals active repositioning into select ADRs and value cyclicals. We recommend a tactical long on the SMA's equity exposure with an entry at $14.50, a target of $17.50 and a stop loss at $12.80, sizing for a medium risk profile and a 180 trading day horizon.
GE Aerospace trades at a premium valuation but sits on a $210B backlog, strong free cash flow, and recent M&A to shore up supply. Public scrutiny of AI-related businesses has created headline noise, but structural demand from commercial, defense and data-center related power needs should keep revenue and margins resilient. This trade idea takes a m…
Jaguar Mining's Turmalina restart materially de-risks near-term production and creates a clearer path to free cash flow. We lay out a tactical long with entry, stop and targets tied to operational milestones and market re-rating potential.
MAXIMUS (MMS) trades at a mid-single-digit PE and double-digit ROE with robust free cash flow. Even assuming a permanent hit from a recent contract change, the shares look cheap relative to intrinsic cash generation and historical trading ranges. This trade idea lays out an entry at $53.00, a stop at $48.00 and a target at $75.00 over a 180-trading…
Grab is trading near $3.18 after a summer slide. Leadership still controls meaningful convertible Class B shares, the firm raised 2026 guidance and expects sizable EBITDA expansion, and a $1.49B deal to acquire 60% of Atome Financial could materially scale lending revenue. That mix makes a disciplined, mid-term long (45 trading days) attractive wit…
Tennant Company has been punished for a botched ERP rollout and the resulting legal and operational headlines. Fundamentals outside the ERP shock are intact: a $1.12B market cap, modest leverage, a growing autonomous robotics unit and a 53-year dividend-raising pedigree. Technicals and short interest show the name is already discounted. I favor a s…
